Oral, mouse LD50: 1000 mg/kg
Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Atazanavir | Roxatidine acetate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Roxatidine acetate. |
| Dabigatran etexilate | Roxatidine acetate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Roxatidine acetate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Roxatidine acetate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazopanib | Roxatidine acetate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Roxatidine acetate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Benzylpenicilloyl polylysine | Roxatidine acetate may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Roxatidine acetate. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Roxatidine acetate. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Roxatidine acetate. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Roxatidine acetate. |
| Bosutinib | Roxatidine acetate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | Roxatidine acetate can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | Roxatidine acetate can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Roxatidine acetate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Roxatidine acetate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexmethylphenidate | The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Roxatidine acetate. |
| Amprenavir | Roxatidine acetate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosamprenavir | Roxatidine acetate can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Roxatidine acetate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Roxatidine acetate can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Roxatidine acetate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Roxatidine acetate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Roxatidine acetate. |
| Nelfinavir | Roxatidine acetate can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nilotinib | Roxatidine acetate can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rilpivirine | Roxatidine acetate can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Roxatidine acetate can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | Roxatidine acetate can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Levothyroxine | Roxatidine acetate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Roxatidine acetate. |
| Captopril | Roxatidine acetate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Roxatidine acetate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Roxatidine acetate may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Roxatidine acetate. |
| Mesalazine | Roxatidine acetate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Roxatidine acetate can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Roxatidine acetate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Roxatidine acetate. |
| Amphetamine | Amphetamine may decrease the sedative activities of Roxatidine acetate. |
| Phentermine | Phentermine may decrease the sedative activities of Roxatidine acetate. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Roxatidine acetate. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Roxatidine acetate. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Roxatidine acetate. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Roxatidine acetate. |
| Mephentermine | Mephentermine may decrease the sedative activities of Roxatidine acetate. |
| MMDA | MMDA may decrease the sedative activities of Roxatidine acetate. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Roxatidine acetate. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Roxatidine acetate. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Roxatidine acetate. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Roxatidine acetate. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Roxatidine acetate. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Roxatidine acetate. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Roxatidine acetate. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Roxatidine acetate. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Roxatidine acetate. |
| Ritobegron | Ritobegron may decrease the sedative activities of Roxatidine acetate. |
| Mephedrone | Mephedrone may decrease the sedative activities of Roxatidine acetate. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Roxatidine acetate. |
| Gepefrine | Gepefrine may decrease the sedative activities of Roxatidine acetate. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Roxatidine acetate. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Roxatidine acetate. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Roxatidine acetate. |
| Ketoconazole | Roxatidine acetate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Roxatidine acetate. |
| Iron Dextran | Roxatidine acetate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron | Roxatidine acetate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate | Roxatidine acetate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prussian blue | Roxatidine acetate can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron sucrose | Roxatidine acetate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric ammonium citrate | Roxatidine acetate can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxsil | Roxatidine acetate can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxides | Roxatidine acetate can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric sulfate | Roxatidine acetate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous bisglycinate | Roxatidine acetate can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gleptoferron | Roxatidine acetate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxide | Roxatidine acetate can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perflubutane | Roxatidine acetate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous sulfate anhydrous | Roxatidine acetate can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium feredetate | Roxatidine acetate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric hydroxide | Roxatidine acetate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric cation | Roxatidine acetate can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous gluconate | Roxatidine acetate can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous succinate | Roxatidine acetate can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous fumarate | Roxatidine acetate can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetraferric tricitrate decahydrate | Roxatidine acetate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxyhydroxide | Roxatidine acetate can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric maltol | Roxatidine acetate can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron polymaltose | Roxatidine acetate can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluconazole | Roxatidine acetate can cause a decrease in the absorption of Fluconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Voriconazole | Roxatidine acetate can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Miconazole | Roxatidine acetate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Posaconazole | Roxatidine acetate can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Abafungin | Roxatidine acetate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ravuconazole | Roxatidine acetate can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Isavuconazonium | Roxatidine acetate can cause a decrease in the absorption of Isavuconazonium resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Isavuconazole | Roxatidine acetate can cause a decrease in the absorption of Isavuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Albaconazole | Roxatidine acetate can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bifonazole | Roxatidine acetate can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |